These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38265945)

  • 21. Autoantibodies in systemic sclerosis.
    Steen VD
    Semin Arthritis Rheum; 2005 Aug; 35(1):35-42. PubMed ID: 16084222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status.
    Kane GC; Varga J; Conant EF; Spirn PW; Jimenez S; Fish JE
    Respir Med; 1996 Apr; 90(4):223-30. PubMed ID: 8736656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiopulmonary Disease Development in Anti-RNA Polymerase III-positive Systemic Sclerosis: Comparative Analyses from an Unselected, Prospective Patient Cohort.
    Hoffmann-Vold AM; Midtvedt Ø; Tennøe AH; Garen T; Lund MB; Aaløkken TM; Andreassen AK; Elhage F; Brunborg C; Taraldsrud E; Molberg Ø
    J Rheumatol; 2017 Apr; 44(4):459-465. PubMed ID: 28089974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis.
    Cottrell TR; Wise RA; Wigley FM; Boin F
    Ann Rheum Dis; 2014 Jun; 73(6):1060-6. PubMed ID: 23606705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres.
    Fransen J; Popa-Diaconu D; Hesselstrand R; Carreira P; Valentini G; Beretta L; Airo P; Inanc M; Ullman S; Balbir-Gurman A; Sierakowski S; Allanore Y; Czirjak L; Riccieri V; Giacomelli R; Gabrielli A; Riemekasten G; Matucci-Cerinic M; Farge D; Hunzelmann N; Van den Hoogen FH; Vonk MC
    Ann Rheum Dis; 2011 Oct; 70(10):1788-92. PubMed ID: 21784727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis.
    Minier T; Guiducci S; Bellando-Randone S; Bruni C; Lepri G; Czirják L; Distler O; Walker UA; Fransen J; Allanore Y; Denton C; Cutolo M; Tyndall A; Müller-Ladner U; Matucci-Cerinic M; ;
    Ann Rheum Dis; 2014 Dec; 73(12):2087-93. PubMed ID: 23940211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoantibody profile in a cohort of Algerian patients with systemic sclerosis.
    Tahiat A; Allam I; Abdessemed A; Mellal Y; Nebbab R; Ladjouze-Rezig A; Djidjik R
    Ann Biol Clin (Paris); 2020 Apr; 78(2):126-133. PubMed ID: 32175889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autopsy versus clinical findings in patients with systemic sclerosis in a case series from patients of the EUSTAR database.
    Sandmeier B; Jäger VK; Nagy G; Carreira PE; Tzankov A; Widuchowska M; Antic M; Distler O; Reichert H; Distler JH; Walker UA; Hügle T
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S75-9. PubMed ID: 26339891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-PM-Scl antibody in patients with systemic sclerosis.
    Koschik RW; Fertig N; Lucas MR; Domsic RT; Medsger TA
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S12-6. PubMed ID: 22261302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature.
    Gelber AC; Manno RL; Shah AA; Woods A; Le EN; Boin F; Hummers LK; Wigley FM
    Medicine (Baltimore); 2013 Jul; 92(4):191-205. PubMed ID: 23793108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual.
    Fasano S; Riccardi A; Messiniti V; Caramaschi P; Rosato E; Maurer B; Smith V; Siegert E; De Langhe E; Riccieri V; Airó P; Mihai C; Avouac J; Zanatta E; Walker UA; Iannone F; García De la Peña Lefebvre P; Distler JHW; Vacca A; Distler O; Kowal-Bielecka O; Allanore Y; Valentini G
    Ann Rheum Dis; 2019 Dec; 78(12):1681-1685. PubMed ID: 31422354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile.
    Vanthuyne M; Smith V; De Langhe E; Van Praet J; Arat S; Depresseux G; Westhovens R; Blockmans D; Badot V; Cogan E; De Keyser F; Houssiau FA
    J Rheumatol; 2012 Nov; 39(11):2127-33. PubMed ID: 22984273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
    Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
    Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort.
    Sujau I; Ng CT; Sthaneshwar P; Sockalingam S; Cheah TE; Yahya F; Jasmin R
    Int J Rheum Dis; 2015 May; 18(4):459-65. PubMed ID: 24618222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis.
    Moinzadeh P; Aberer E; Ahmadi-Simab K; Blank N; Distler JH; Fierlbeck G; Genth E; Guenther C; Hein R; Henes J; Herich L; Herrgott I; Koetter I; Kreuter A; Krieg T; Kuhr K; Lorenz HM; Meier F; Melchers I; Mensing H; Mueller-Ladner U; Pfeiffer C; Riemekasten G; Sárdy M; Schmalzing M; Sunderkoetter C; Susok L; Tarner IH; Vaith P; Worm M; Wozel G; Zeidler G; Hunzelmann N;
    Ann Rheum Dis; 2015 Apr; 74(4):730-7. PubMed ID: 24389298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nailfold capillaroscopy in systemic sclerosis: data from the EULAR scleroderma trials and research (EUSTAR) database.
    Ingegnoli F; Ardoino I; Boracchi P; Cutolo M;
    Microvasc Res; 2013 Sep; 89():122-8. PubMed ID: 23792167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic dyspnea with Raynaud's phenomenon and elevated ANA: A diagnosis of systemic sclerosis sine scleroderma.
    Chong WH; Saha BK; Beegle S
    Am J Med Sci; 2023 Feb; 365(2):198-204. PubMed ID: 35276077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine.
    Lescoat A; Bellando-Randone S; Campochiaro C; Del Galdo F; Denton CP; Farrington S; Galetti I; Khanna D; Kuwana M; Truchetet ME; Allanore Y; Matucci-Cerinic M
    Lancet Rheumatol; 2023 Nov; 5(11):e683-e694. PubMed ID: 38251534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.